[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
ONLINE FIRST
June 20, 2012

A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory ActionsOpportunities Provided by a New IOM Report

Author Affiliations

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington and Group Health Research Institute, Group Health Cooperative, Seattle, Washington (Dr Psaty); Center for Bioethics, Indiana University, Indianapolis (Dr Meslin); and Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK (Dr Breckenridge).

JAMA. 2012;307(23):2491-2492. doi:10.1001/jama.2012.5545

In the postmarket setting, the regulation of medicines requires an assessment of the balance between their benefits and risks and, as new information becomes available, may require regulatory actions that range from changes in the product label to withdrawal of a drug from the market. A series of unforeseen consequences of drug administration to vulnerable patients has shaped the modern history of the regulation of medications. In the 1960s, for instance, thalidomide given to pregnant women resulted in birth defects or death in several thousand of their offspring. The framework for modern drug regulation largely emerged from the development of various measures to prevent similar drug-safety disasters.

First Page Preview View Large
First page PDF preview
First page PDF preview
×